Paroxysmal nocturnal hemoglobinuria has long been one of hematology’s cruelest puzzles: a rare, acquired stem-cell mutation that leaves red blood cells defenseless against the body’s own com ...
Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
Complement pathway proteins are involved in immunoglobulin A-containing immune complex (IgA-IC) formation and deposition in the kidneys. Elevated complement factor H-related protein 1 (CFHR1) may be a ...
We investigated whether serum complement C3 and C4 levels and the C4/C3 ratio at disease onset were associated with clinical features, renal involvement, and ...
Mannose-binding lectin (MBL) is a soluble C-type lectin that recognises carbohydrate patterns on a wide range of pathogens and initiates the lectin pathway of complement activation. Upon binding to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results